SCHEMBL5579217

SCHEMBL5579217

CC(C)(C)c1c[nH]c(-c2n[nH]cc2NC(=O)c2c(F)cccc2F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 3/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
HTT P42858 1/20 0.37
NOD2 Q9HC29 1/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CDK1 P06493 3/20 0.36
CDK2 P24941 3/20 0.36
CCNB1 P14635 2/20 0.36
CCNA2 P20248 2/20 0.36
CCNA1 P78396 1/20 0.36
ROCK1 Q13464 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578191 0.81 MEN1 (0.40) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5578150 0.80 CDK1 (0.45) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL14511654 0.80 CDK2 (0.38) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5578299 0.80 CDK1 (0.43) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5578275 0.79 JAK2 (0.46) MEN1KMT2ARAB9AJAK2JAK1
SCHEMBL5578220 0.78 CDK1 (0.41) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5578113 0.78 MEN1 (0.43) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5578253 0.77 MEN1 (0.40) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5579242 0.76 ABL1 (0.38) MEN1KMT2AJAK2JAK1TYK2
SCHEMBL3586136 0.76 MEN1 (0.43) MEN1KMT2APOLBRAB9AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105900-A1 Pharmaceutical compounds AURKA, AURKC, CDK1 MEN1 1585/4885KMT2A 1706/4885POLB 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.